, Fact or Fiction: What Healthcare Professionals Need to Know about Pharmaceutical Marketing in the European Union -Health Action International, Health Action International, 2016.

, Understanding and responding to pharmaceutical promotion: a practical guide, 2009.

A. Fabbri, . Santos-ancel-la, S. Mezinska, S. Mulinari, and B. Mintzes, Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries, Int J Health Policy Manag, vol.7, pp.504-513, 2018.

M. Wilson, Is transparency really a panacea?, J R Soc Med, vol.107, pp.216-223, 2014.

B. Hauray, Dispositifs de transparence et régulation des conflits d'intérêts dans le secteur du médicament, Rev Fr Adm Publique, issue.1, pp.49-61, 2018.

, relative au renforcement de la sécurité sanitaire du médicament et des produits de santé, 2011.

J. Bezin, M. Duong, and R. Lassalle, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf, vol.26, pp.954-62, 2017.

, Paying for Performance in Health Care: Implications for Health System Performance and Accountability, 2014.

D. Darmon, M. Belhassen, S. Quien, C. Langlois, P. Staccini et al., Factors associated with drug prescription in general practice: a multicenter cross-sectional study, Sante Publique, vol.27, pp.353-62, 2015.

A. Maladie, &. Medic, and . Am, Données mensuelles et annuelles sur les médicaments remboursés par l'Assurance Maladie

A. Maladie, La rémunération sur objectif de santé publique -Bilan à 5 ans et présentation du nouveau dispositif, 1929.

J. Ioannidis, Y. J. Tan, and M. R. Blum, Limitations and Misinterpretations of E-Values for Sensitivity Analyses of Observational Studies, Ann Intern Med, vol.170, p.108, 2019.

L. Scailteux, C. Droitcourt, F. Balusson, E. Nowak, S. Kerbrat et al., French administrative health care database (SNDS): The value of its enrichment. Therap, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01940381

S. E. Hadland, A. Rivera-aguirre, B. Marshall, and M. Cerdá, Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses, JAMA Netw Open, vol.2, p.186007, 2019.

T. G. Rhee and J. S. Ross, Association Between Industry Payments to Physicians and Gabapentinoid Prescribing, JAMA Intern Med, 2019.

S. Chapman, P. Durieux, and T. Walley, Good prescribing practice, Regulating pharmaceuticals in europe: Striving for efficiency, equity and quality, pp.144-57, 2004.

A. J. Walker, H. J. Curtis, R. Croker, S. Bacon, and B. Goldacre, Measuring the Impact of an Open Web-Based Prescribing Data Analysis Service on Clinical Practice: Cohort Study on NHS England Data, J Med Internet Res, vol.21, p.10929, 2019.

. Prescrire, Pay for performance: financial rewards without improving quality of care, Prescrire Int, vol.24, p.279, 2015.

. Quotidien-du-médecin, P4P, téléservices, dépassements, maîtrise, le patron de la CNAM à l'offensive sur tous les fronts. Quotidien du médecin, 2012.

G. K. Spurling, P. R. Mansfield, and B. D. Montgomery, Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review, PLoS Med, vol.7, p.1000352, 2010.

H. Brax, R. Fadlallah, and L. Al-khaled, Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis, PLoS One, vol.12, p.175493, 2017.

F. Fickweiler, W. Fickweiler, and E. Urbach, Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review, BMJ Open, vol.7, p.16408, 2017.

J. Mejia, A. Mejia, and F. Pestilli, Open data on industry payments to healthcare providers reveal potential hidden costs to the public, Nat Commun, vol.10, pp.1-8, 2019.

M. Sharma, A. Vadhariya, M. L. Johnson, Z. A. Marcum, and H. M. Holmes, Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data, BMC Health Serv Res, vol.18, p.236, 2018.

J. S. Yeh, J. M. Franklin, J. Avorn, J. Landon, and A. S. Kesselheim, Association of Industry Payments to Physicians With the Prescribing of Brandname Statins in Massachusetts, JAMA Intern Med, vol.176, pp.763-771, 2016.

J. Qian, R. A. Hansen, D. Surry, J. Howard, Z. Kiptanui et al., Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing, Pharmacoepidemiol Drug Saf, vol.26, pp.819-845, 2017.

R. H. Perlis and C. S. Perlis, Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs, PLoS One, vol.11, p.1, 2016.

. Ministère-de-l'économie and . Trésor-Éco, Quelle politique pour poursuivre la diffusion des médicaments génériques?, 0199.

D. Grande, D. L. Frosch, A. W. Perkins, and B. E. Kahn, Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Preferences, Arch Intern Med, vol.169, pp.887-93, 2009.

B. Lo and D. Grady, Payments to Physicians: Does the Amount of Money Make a Difference?, JAMA, vol.317, pp.1719-1739, 2017.

C. Dejong, T. Aguilar, C. Tseng, G. A. Lin, W. J. Boscardin et al., Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries, JAMA Intern Med, vol.176, p.1114, 2016.

S. Sah and A. Fugh-berman, Physicians under the influence: social psychology and industry marketing strategies, J Law Med Ethics, vol.41, pp.665-72, 2013.